The rate of arteriovenous fistula (AVF) maturation failure remains unacceptably high despite continuous efforts on technique improvement and careful pre-surgery planning. In fact, half of all newly created AVFs are unable to be used for hemodialysis (HD) without a salvage procedure. While vascular stenosis in the venous limb of the access is the culprit, the underlying factors leading to vascular narrowing and AVF maturation failure are yet to be determined. We have recently demonstrated that AVF non-maturation is associated with post-operative medial fibrosis and fibrotic stenosis, and post-operative intimal hyperplasia (IH) exacerbates the situation. Multiple pathological processes and signaling pathways are underlying the stenotic remodeling of the AVF. Our group has recently indicated that a pro-inflammatory cytokine platelet factor 4 (PF4/CXCL4) is upregulated in veins that fail to mature after AVF creation. Platelet factor 4 is a fibrosis marker and can be detected in vascular stenosis tissue, suggesting that it may contribute to AVF maturation failure through stimulation of fibrosis and development of fibrotic stenosis. Here, we present an overview of the how PF4-mediated fibrosis determines AVF maturation failure.
BresciaMJCiminoJEAppelK, et al. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. New Engl J Med1966; 275(20): 1089–1092.
2.
USRDS. USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2020.
3.
FoundationNK. 2006 updates clinical practice guidelines and recommendations. New York, NY: National Kidney Foundation, 2006.
4.
PolkinghorneKRChinGKMacGinleyRJ, et al. KHA-CARI Guideline: vascular access – central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology2013; 18(11): 701–705.
5.
StolicR. Most important chronic complications of arteriovenous fistulas for hemodialysis. Med Princ Pract2013; 22(3): 220–228.
6.
HicksCWCannerJKArhuideseI, et al. Mortality benefits of different hemodialysis access types are age dependent. J. Vasc. Surg2015; 61(2): 449–456.
7.
LeermakersJJBodeASVaidyaA, et al. Cost-effectiveness of vascular access for haemodialysis: arteriovenous fistulas versus arteriovenous grafts. Eur J Vasc Endovasc Surg2013; 45(1): 84–92.
8.
MalasMBCannerJKHicksCW, et al. Trends in incident hemodialysis access and mortality. JAMA Surg2015; 150(5): 441–448.
9.
NassarGMAyusJC. Infectious complications of the hemodialysis access. Kidney Int2001; 60(1): 1–13.
10.
RamanathanVChiuEJThomasJT, et al. Healthcare costs associated with hemodialysis catheter-related infections: a single-center experience. Infect. Control Hosp. Epidemiol2007; 28(5): 606–609.
11.
WooKDorosGNgT, et al. Comparison of the efficacy of upper arm transposed arteriovenous fistulae and upper arm prosthetic grafts. J Vasc Surg2009; 50(6): 1405–11.e1.
12.
AlmasriJAlsawasMMainouM, et al. Outcomes of vascular access for hemodialysis: A systematic review and meta-analysis. J. Vasc. Surg2016; 64(1): 236–243.
13.
MuradMHElaminMBSidawyAN, et al. Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis. J. Vasc. Surg2008; 48(5 Suppl): 34S–47S.
14.
LokCEHuberTSLeeT, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis2020; 75(4 Suppl 2): S1–S164.
15.
Al-JaishiAALokCEGargAX, et al. Vascular access creation before hemodialysis initiation and use: a population-based cohort study. Clin J Am Soc Nephrol2015; 10(3): 418–427.
16.
SchinstockCAAlbrightRCWilliamsAW, et al. Outcomes of arteriovenous fistula creation after the fistula first initiative. Clin J Am Soc Nephrol2011; 6(8): 1996–2002.
17.
Al-JaishiAAOliverMJThomasSM, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis2014; 63(3): 464–478.
MayaIDO–NealJCYoungCJ, et al. Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts. Clin J Am Soc Nephrol2009; 4(1): 86–92.
20.
PisoniRLZepelLPortFK, et al. Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. Am J Kidney Dis2015; 65(6): 905–915.
21.
RavaniPSpergelLMAsifA, et al. Clinical epidemiology of arteriovenous fistula in 2007. J. Nephrol2007; 20(2): 141–149.
22.
DemberLMBeckGJAllonM, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008; 299(18): 2164–2171.
23.
LokCEAllonMMoistL, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol2006; 17(11): 3204–3212.
24.
TordoirJHMZonnebeldNvan LoonMM, et al. Surgical and endovascular intervention for dialysis access maturation failure during and after arteriovenous fistula surgery: review of the evidence. Eur J Vasc Endovasc Surg2018; 55(2): 240–248.
25.
AllonMGreeneTDemberLM, et al. Association between preoperative vascular function and postoperative arteriovenous fistula development. J Am Soc Nephrol2016; 27(12): 3788–3795.
26.
SimoneSLoverreACarielloM, et al. Arteriovenous fistula stenosis in hemodialysis patients is characterized by an increased adventitial fibrosis. J Nephrol2014; 27(5): 555–562.
27.
MartinezLDuqueJCTabbaraM, et al. Fibrotic venous remodeling and nonmaturation of arteriovenous fistulas. J Am Soc Nephrol2018; 29(3): 1030–1040.
28.
BerceliSAJiangZKlingmanNV, et al. Early differential MMP-2 and -9 dynamics during flow-induced arterial and vein graft adaptations. J. Surg. Res2006; 134(2): 327–334.
29.
BrahmbhattARemuzziAFranzoniM, et al. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int2016; 89(2): 303–316.
30.
LeeESShenQPittsRL, et al. Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation. J Vasc Surg2011; 54(2): 454–460.
31.
AidoudiSBikfalviA. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb. Haemost2010; 104(5): 941–948.
32.
SchwarzKBRosensweigJSharmaS, et al. Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J. Pediatr. Gastroenterol. Nutr2003; 37(2): 187–191.
33.
ZaldivarMMPauelsKvon HundelshausenP, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology2010; 51(4): 1345–1353.
34.
MartinezLTabbaraMDuqueJC, et al. Transcriptomics of human arteriovenous fistula failure: genes associated with nonmaturation. Am J Kidney Dis2019; 74(1): 73–81.
35.
HendersonNCRiederFWynnTA. Fibrosis: from mechanisms to medicines. Nature2020; 587(7835): 555–566.
36.
BatallerRBrennerDA. Liver fibrosis. J. Clin. Investig2005; 115(2): 209–218.
37.
RockeyDCBellPDHillJA. Fibrosis: a common pathway to organ injury and failure. New Engl J Med2015; 372(12): 1138–1149.
38.
WynnTA. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med2011; 208(7): 1339–1350.
39.
KarsdalMANielsenSHLeemingDJ, et al. The good and the bad collagens of fibrosis: their role in signaling and organ function. Adv Drug Deliv Rev2017; 121:43–56.
40.
UrbanMLManentiLVaglioA. Fibrosis: a common pathway to organ injury and failure. New Engl J Med2015; 373(1): 95–96.
41.
WynnTARamalingamTR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med2012; 18(7): 1028–1040.
42.
DuffieldJS. Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Investig2014; 124(6): 2299–2306.
43.
ElmufdiFHenkeCAPerlmanDM, et al. Novel mechanisms and treatment of idiopathic pulmonary fibrosis. Discov. Med2015; 20(109): 145–153.
44.
MallatALotersztajnS. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am. J. Physiol. Cell Physiol2013; 305(8): C789–C799.
45.
MurthaLASchuligaMJMabotuwanaNS, et al. The processes and mechanisms of cardiac and pulmonary fibrosis. Front Physiol2017; 8:777.
46.
LanTHHuangXQTanHM. Vascular fibrosis in atherosclerosis. Cardiovasc Pathol2013; 22(5): 401–407.
PonticosMSmithBD. Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res2014; 28(1): 25–39.
49.
TouyzRM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp. Physiol2005; 90(4): 449–455.
50.
EmingSAMartinPTomic-CanicM. Wound repair and regeneration: mechanisms, signaling, and translation. Sci. Transl. Med2014; 6(265): 265sr6.
51.
KrenkelOTackeF. Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol2017; 17(5): 306–321.
52.
VannellaKMWynnTA. Mechanisms of organ injury and repair by macrophages. Annu Rev Physiol2017; 79:593–617.
53.
WynnTAVannellaKM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity2016; 44(3): 450–462.
54.
WynnTA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol2004; 4(8): 583–594.
55.
HinzBPhanSHThannickalVJ, et al. The myofibroblast: one function, multiple origins. Am. J. Pathol2007; 170(6): 1807–1816.
56.
MohindraRAgrawalDKThankamFG. Altered vascular extracellular matrix in the pathogenesis of Atherosclerosis. J Cardiovasc Transl Res2021; 14(4): 647–660.
57.
HardieWDGlasserSWHagoodJS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol2009; 175(1): 3–16.
58.
JelaskaAKornJH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum2000; 43(10): 2230–2239.
59.
PechkovskyDVHackettTLAnSS, et al. Human lung parenchyma but not proximal bronchi produces fibroblasts with enhanced TGF-β signaling and α-SMA expression. Am J Respir Cell Mol Biol2010; 43(6): 641–651.
60.
PopovYSchuppanD. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology2009; 50(4): 1294–1306.
61.
CassimanDLibbrechtLDesmetV, et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J. Hepatol2002; 36(2): 200–209.
62.
UrushiyamaHTerasakiYNagasakaS, et al. Role of α1 and α2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts. Lab Invest2015; 95(8): 872–885.
63.
LiuBItohHLouieO, et al. The role of phospholipase C and phosphatidylinositol 3-kinase in vascular smooth muscle cell migration and proliferation. J. Surg. Res2004; 120(2): 256–265.
64.
AdlerMMayoAZhouX, et al. Principles of cell circuits for tissue repair and fibrosis. iScience2020; 23(2): 100841.
65.
HendersonNCMackinnonACFarnworthSL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol2008; 172(2): 288–298.
66.
LodygaMCambridgeEKarvonenHM, et al. Cadherin-11-mediated adhesion of macrophages to myofibroblasts establishes a profibrotic niche of active TGF-β. Sci Signal2019; 12(564): eaao3496.
67.
PakshirPHinzB. The big five in fibrosis: macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biol2018; 68–69:81–93.
68.
RamachandranPDobieRWilson-KanamoriJR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature2019; 575(7783): 512–518.
69.
ShookBAWaskoRRRivera-GonzalezGC, et al. Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair. Science2018; 362(6417): eaar2971.
70.
ZhouXFranklinRAAdlerM, et al. Circuit design features of a stable two-cell system. Cell2018; 172(4): 744–757.e17.
71.
El AghaEKramannRSchneiderRK, et al. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell2017; 21(2): 166–177.
72.
KisselevaTCongMPaikY, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci2012; 109(24): 9448–9453.
73.
NattelS. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol2017; 3(5): 425–435.
74.
TroegerJSMederackeIGwakGY, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology2012; 143(4): 1073–83.e22.
75.
RockeyDCHoussetCNFriedmanSL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J. Clin. Investig1993; 92(4): 1795–1804.
76.
MackMYanagitaM. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int2015; 87(2): 297–307.
77.
HarveyAMontezanoACLopesRA, et al. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol2016; 32(5): 659–668.
78.
BasheyRICoxRMcCannJ, et al. Changes in collagen biosynthesis, types, and mechanics of aorta in hypertensive rats. J. Lab. Clin. Med1989; 113(5): 604–611.
79.
LaviadesCVaroNFernándezJ, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation1998; 98(6): 535–540.
80.
BanCRTwiggSM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manag2008; 4(3): 575–596.
81.
LakattaEG. The reality of aging viewed from the arterial wall. Artery Res2013; 7(2): 73–80.
82.
ArribasSMHinekAGonzálezMC. Elastic fibres and vascular structure in hypertension. Pharmacol. Ther2006; 111(3): 771–791.
83.
LakattaEGLevyD. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I. Aging arteries: a “set up” for vascular disease. Circulation2003; 107(1): 139–146.
84.
EddyAALiuEMcCullochL. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int1996; 50(4): 1139–1149.
85.
EddyAA. Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int1998; 53(5): 1182–1189.
86.
ChadeARMushinOPZhuX, et al. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension2005; 46(4): 772–779.
87.
DingGvan GoorHRicardoSD, et al. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int1997; 51(1): 147–154.
88.
SongCYKimBCHongHK, et al. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-beta signaling in mesangial cells. Kidney Int2005; 67(5): 1743–1752.
89.
TestaiLBrancaleoneVFloriL, et al. Modulation of EndMT by hydrogen sulfide in the prevention of cardiovascular fibrosis. Antioxidants2021; 10(6): 910.
90.
TyagiSC, et al. Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem1998; 181(1–2): 107–116.
91.
MujumdarVSHaydenMRTyagiSC. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol2000; 183(1): 28–36.
92.
AndreeaSIMarietaCAncaD. AGEs and glucose levels modulate type I and III procollagen mRNA synthesis in dermal fibroblasts cells culture. Exp. Diabetes Res2008; 2008:473603.
93.
LeeheyDJSinghAKAlaviN, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl2000; 77:S93–S98.
94.
Martínez-MartínezEMianaMJurado-LópezR, et al. The potential role of leptin in the vascular remodeling associated with obesity. Int. J. Obes2014; 38(12): 1565–1572.
95.
JiaGSowersJR. Endothelial dysfunction potentially interacts with impaired glucose metabolism to increase cardiovascular risk. Hypertension2014; 64(6): 1192–1193.
96.
BöttingerEPBitzerM. TGF-beta signaling in renal disease. J Am Soc Nephrol2002; 13(10): 2600–2610.
97.
EddyAA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl2014; 4(1): 2–8.
ThannickalVJToewsGBWhiteESMartinezFJ, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med2004; 55:395–417.
100.
AllenRJ, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med2017; 5(11): 869–880.
101.
FingerlinTEMurphyEZhangW, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet2013; 45(6): 613–620.
102.
GansnerJMRosasIOEbertBL. Pulmonary fibrosis, bone marrow failure, and telomerase mutation. New Engl. J. Med2012; 366(16): 1551–1553.
103.
HunninghakeGMHatabuHOkajimaY, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. New Engl J Med2013; 368(23):2192–2200.
104.
KimHYParkJELeeSC, et al. Genotype-related clinical characteristics and myocardial fibrosis and their association with prognosis in hypertrophic cardiomyopathy. J Clin Med2020; 9(6): 1671.
105.
YoungCNJGosselinMRFRumneyR, et al. Total absence of dystrophin expression exacerbates ectopic myofiber calcification and fibrosis and alters macrophage infiltration patterns. Am J Pathol2020; 190(1): 190–205.
106.
BiernackaADobaczewskiMFrangogiannisNG. TGF-β signaling in fibrosis. Growth Factors2011; 29(5): 196–202.
107.
LeaskAAbrahamDJ. TGF-beta signaling and the fibrotic response. FASEB J2004; 18(7): 816–827.
108.
MengXMNikolic-PatersonDJLanHY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol2016; 12(6): 325–338.
109.
PiersmaBBankRABoersemaM. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med2015; 2:59.
110.
ChenBHuangSSuY, et al. Macrophage Smad3 protects the infarcted heart, stimulating phagocytosis and regulating inflammation. Circ Res2019; 125(1): 55–70.
YamanakaMShegogueDPeiH, et al. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J Biol Chem2004; 279(52): 53994–54001.
115.
LodygaMHinzB. TGF-β1: a truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol2020; 101:123–139.
116.
HeldinCHMoustakasA. Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol2016; 8(8): a022053.
117.
HoriguchiMOtaMRifkinDB. Matrix control of transforming growth factor-β function. J Biochem2012; 152(4): 321–329.
118.
AnnesJPMungerJSRifkinDB. Making sense of latent TGFbeta activation. J. Cell Sci2003; 116(Pt 2): 217–224.
119.
Bourd-BoittinKBonnierDLeymeA, et al. Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. Hepatology2011; 54(6): 2173–2184.
120.
BriassouliPRifkinDClancyRM, et al. Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-β and potentiates fibrosis. J Immunol2011; 187(10): 5392–5401.
121.
EdgttonKLGowRMKellyDJ, et al. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int2004; 66(1): 68–76.
122.
KhalilNCorneSWhitmanC, et al. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol1996; 15(2): 252–259.
123.
OkunoMAkitaKMoriwakiH, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology2001; 120(7): 1784–1800.
124.
SheaBSProbstCKBrazeePL, et al. Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight2017; 2(9): e86608.
125.
YaoYHuCSongQ, et al. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc Res2020; 116(5): 956–969.
126.
AsanoYIhnHYamaneK, et al. Increased expression of integrin αvβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol2005; 175(11): 7708–7718.
127.
AsanoYIhnHYamaneK, et al. Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum2005; 52(9): 2897–2905.
128.
HäkkinenLKoivistoLGardnerH, et al. Increased expression of beta6-integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol2004; 164(1): 229–242.
129.
MungerJSHuangXKawakatsuH, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell1999; 96(3): 319–328.
130.
SarrazyVKoehlerAChowML, et al. Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc Res2014; 102(3): 407–417.
131.
ScottonCJKrupiczojcMAKönigshoffM, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Investig2009; 119(9): 2550–2563.
132.
TatlerALJohnAEJollyL, et al. Integrin αvβ5-mediated TGF-β activation by airway smooth muscle cells in asthma. J Immunol2011; 187(11): 6094–6107.
133.
FrangogiannisNG. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev2012; 92(2): 635–688.
134.
KlingbergFChauGWalravenM, et al. The ED-A domain enhances the capacity of fibronectin to store latent TGF-β binding protein-1 in the fibroblast matrix. J Cell Sci2018; 131(5): jcs201293.
135.
LiuGCooleyMAJarnickiAG, et al. Fibulin-1c regulates transforming growth factor-β activation in pulmonary tissue fibrosis. JCI Insight2019; 5(16): e124529.
136.
SeriniGBochaton-PiallatMLRoprazP, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J. Cell Biol1998; 142(3): 873–881.
137.
RobertsonIBRifkinDB. Regulation of the bioavailability of TGF-β and TGF-β-related proteins. Cold Spring Harb Perspect Biol2016; 8(6): a021907.
138.
AmălineiCCăruntuIDGiuşcăSE, et al. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol2010; 51(2): 215–228.
139.
GiannandreaMParksWC. Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model Mech2014; 7(2): 193–203.
140.
JiaGHillMASowersJR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res2018; 122(4): 624–638.
141.
PrakobwongSYongvanitPHirakuY, et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer2010; 127(11): 2576–2587.
142.
VerrecchiaFMauvielA. Transforming growth factor-beta and fibrosis. World J Gastroenterol2007; 13(22): 3056–3062.
143.
MishraRCoolBLLaderouteKR, et al. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem2008; 283(16): 10461–10469.
144.
MorikawaMDerynckRMiyazonoK. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol2016; 8(5): a021873.
145.
SchnaperHWHayashidaTHubchakSC, et al. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol2003; 284(2): F243–F252.
146.
DattaPKBlakeMCMosesHL. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta -induced physical and functional interactions between Smads and Sp1. J Biol Chem2000; 275(51): 40014–40019.
147.
DesmoulièreAGeinozAGabbianiF, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol1993; 122(1): 103–111.
148.
DouilletCDVelardeVChristopherJT, et al. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am J Physiol Heart Circ Physiol2000; 279(6): H2829–H2837.
149.
O’CallaghanCJWilliamsB. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-beta(1). Hypertension2000; 36(3): 319–324.
150.
RobertsABSpornMBAssoianRK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA1986; 83(12): 4167–4171.
151.
SamarakoonRHigginsSPHigginsCE, et al. The TGF-β1/p53/PAI-1 signaling axis in vascular senescence: role of caveolin-1. Biomolecules2019; 9(8): 341.
152.
HinzBMastrangeloDIselinCE, et al. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am. J. Pathol2001; 159(3): 1009–1020.
RupérezMLorenzoOBlanco-ColioLM, et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation2003; 108(12): 1499–1505.
155.
ThumTGrossCFiedlerJ, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature2008; 456(7224): 980–984.
156.
FunabaMZimmermanCMMathewsLS. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem2002; 277(44): 41361–41368.
157.
FurukawaFMatsuzakiKMoriS, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology2003; 38(4): 879–889.
158.
KretzschmarMDoodyJTimokhinaI, et al. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev1999; 13(7): 804–816.
159.
LeeMKPardouxCHallMC, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J2007; 26(17): 3957–3967.
160.
SeayUSeddingDKrickS, et al. Transforming growth factor-beta-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther2005; 315(3): 1005–1012.
161.
YoshidaKMatsuzakiKMoriS, et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol2005; 166(4): 1029–1039.
162.
YuBSladojevicNBlairJE, et al. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Expert Opin Ther Targets2020; 24(1): 47–62.
163.
ZhangYE. Non-Smad signaling pathways of the TGF-β family. Cold Spring Harb Perspect Biol2017; 9(2): a022129.
164.
DerynckRZhangYE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature2003; 425(6958): 577–584.
165.
DawsonKWakiliROrdögB, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation2013; 127(14): 1466–1475e1.
166.
LaknerAMSteuerwaldNMWallingTL, et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology2012; 56(1): 300–310.
167.
PuttaSLantingLSunG, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol2012; 23(3): 458–469.
168.
van RooijEOlsonEN. Searching for miR-acles in cardiac fibrosis. Circ Res2009; 104(2): 138–140.
169.
LiYJiangDLiangJ, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med2011; 208(7): 1459–1471.
170.
KoelinkPJOverbeekSABraberS, et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut2014; 63(4): 578–587.
171.
RodríguezDMorrisonCJOverallCM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta2010; 1803(1): 39–54.
172.
AktharSPatelDFBealeRC, et al. Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection. Nat Commun2015; 6:8423.
173.
Ruiz-OrtegaMLorenzoORupérezM, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension2001; 38(6): 1382–1387.
174.
BorderWANobleNA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension1998; 31(1 Pt 2): 181–188.
175.
WolfG. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int2006; 70(11): 1914–1919.
176.
SongJJYangMLiuY, et al. MicroRNA-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. Eur. J. Pharmacol2020; 883:173374.
177.
XuRZhangZZChenLJ, et al. Ascending aortic adventitial remodeling and fibrosis are ameliorated with Apelin-13 in rats after TAC via suppression of the miRNA-122 and LGR4-β-catenin signaling. Peptides2016; 86:85–94.
178.
GibbonsGHPrattREDzauVJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Investig1992; 90(2): 456–461.
179.
ItohHMukoyamaMPrattRE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Investig1993; 91(5): 2268–2274.
180.
Rodríguez-VitaJSánchez-LópezEEstebanV, et al. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation2005; 111(19): 2509–2517.
181.
SucoskyPBalachandranKElhammaliA, et al. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-β1-dependent pathway. Arterioscler Thromb Vasc Biol2008; 29(2): 254–260.
182.
RhyuDYYangYHaH, et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol2005; 16(3): 667–675.
183.
CarverKASmithTLGallagherPE, et al. Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels. Microcirculation2015; 22(1): 19–27.
184.
MontezanoACBurgerDParaviciniTM, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res2010; 106(8): 1363–1373.
185.
QiGJiaLLiY, et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc. Toxicol2011; 11(2): 157–167.
186.
WeigertCBrodbeckKKlopferK, et al. Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia. Diabetologia2002; 45(6): 890–898.
187.
ChenBWangPBremA, et al. Mineralocorticoid receptor: a hidden culprit for hemodialysis vascular access dysfunction. EBioMedicine2019; 39:621–627.
188.
EhsanAMcGrawAPAronovitzMJ, et al. Mineralocorticoid receptor antagonism inhibits vein graft remodeling in mice. J Thorac Cardiovasc Surg2013; 145(6): 1642–1649.e1.
189.
IshidoyaSMorrisseyJMcCrackenR, et al. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int1995; 47(5): 1285–1294.
190.
Ruiz-OrtegaMGonzálezSSerónD, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int1995; 48(6): 1778–1791.
191.
ZhangZChenLZhongJ, et al. ACE2/Ang-(1-7) signaling and vascular remodeling. Sci. China Life Sci2014; 57(8): 802–808.
192.
SongBZhangZZZhongJC, et al. Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway. Circ J2013; 77(12): 2997–3006.
193.
ZhongJBasuRGuoD, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation2010; 122(7): 717–728.
194.
SampaioWOSouza dos SantosRAFaria-SilvaR, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension2007; 49(1): 185–192.
195.
SongBJinHYuX, et al. Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regul Pept2013; 185:44–51.
196.
TallantEAFerrarioCMGallagherPE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol2005; 289(4): H1560–H1566.
197.
LaggnerHHermannMEsterbauerH, et al. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. J. Hypertens2007; 25(10): 2100–2104.
198.
MengGMaYXieL, et al. Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases. Br J Pharmacol2015; 172(23): 5501–5511.
199.
SnijderPMFrenayARde BoerRA, et al. Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats. Br J Pharmacol2015; 172(6): 1494–1504.
200.
SenUMishraPKTyagiN, et al. Homocysteine to hydrogen sulfide or hypertension. Cell Biochem. Biophys2010; 57(2–3): 49–58.
HsiehCCPapaconstantinouJ. The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid. Mech. Ageing Dev2002; 123(11): 1423–1435.
203.
LiZLiJBuX, et al. Age-induced augmentation of p38 MAPK phosphorylation in mouse lung. Exp Gerontol2011; 46(8): 694–702.
204.
WuZYuYLiuC, et al. Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with Arginase-II and S6K1 signaling pathway. Aging2015; 7(1): 70–81.
205.
BrionesAMNguyen Dinh CatACalleraGE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension2012; 59(5): 1069–1078.
206.
SavoiaCTouyzRMAmiriF, et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension2008; 51(2): 432–439.
207.
BrownNJNakamuraSMaL, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int2000; 58(3): 1219–1227.
208.
LeeYSKimJAKimKL, et al. Aldosterone upregulates connective tissue growth factor gene expression via p38 MAPK pathway and mineralocorticoid receptor in ventricular myocytes. J Korean Med Sci2004; 19(6): 805–811.
HafiziSWhartonJChesterAH, et al. Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem2004; 14(4–6): 285–292.
211.
HorstmeyerALichtCScherrG, et al. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J2005; 272(24): 6297–6309.
212.
MakitaZBucalaRRayfieldEJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet1994; 343(8912): 1519–1522.
213.
CooperME. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am. J. Hypertens2004; 17(12 Pt 2): 31S–38S.
214.
ReddyGK. AGE-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc. Res2004; 68(2): 132–142.
215.
ThrockmortonDCBrogdenAPMinB, et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int1995; 48(1): 111–117.
216.
TorjesenAASigurðssonSWestenbergJJ, et al. Pulse pressure relation to aortic and left ventricular structure in the age, gene/environment susceptibility (AGES)-Reykjavik study. Hypertension2014; 64(4): 756–761.
217.
GalisZSKhatriJJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res2002; 90(3): 251–262.
218.
NewbyAC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res2006; 69(3): 614–624.
219.
DeenadayaluVPuttabyatappaYLiuAT, et al. Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cgmp-dependent protein kinase. Am J Physiol Heart Circ Physiol2012; 302(1): H115–H123.
220.
ShindeAVSuYPalanskiBA, et al. Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. J Mol Cell Cardiol2018; 117:36–48.
221.
SteppanJBergmanYViegasK, et al. Tissue transglutaminase modulates vascular stiffness and function through crosslinking-dependent and crosslinking-independent functions. J Am Heart Assoc2017; 6(2): e004161.
222.
IvanovSScallanJPKimKW, et al. CCR7 and IRF4-dependent dendritic cells regulate lymphatic collecting vessel permeability. J Clin Investig2016; 126(4): 1581–1591.
223.
SurendranKSchiaviSHruskaKA. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol2005; 16(8): 2373–2384.
224.
WeiJMelichianDKomuraK, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?Arthritis Rheum2011; 63(6): 1707–1717.
225.
KönigshoffMKramerMBalsaraN, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Investig2009; 119(4): 772–787.
226.
WangDDaiCLiY, et al. Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria. Kidney Int2011; 80(11): 1159–1169.
227.
PoonRNikSAAhnJ, et al. Beta-catenin and transforming growth factor beta have distinct roles regulating fibroblast cell motility and the induction of collagen lattice contraction. BMC Cell Biol2009; 10:38.
228.
FengWLiWLiuW, et al. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol2009; 87(3): 212–218.
229.
MengFWangKAoyamaT, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology2012; 143(3): 765–776.e3.
230.
ParkMJMoonSJLeeEJ, et al. IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis. Front Immunol2018; 9:1611.
231.
SunBWangHZhangL, et al. Role of interleukin 17 in TGF-β signaling-mediated renal interstitial fibrosis. Cytokine2018; 106:80–88.
232.
WangBZWangLPHanH, et al. Interleukin-17A antagonist attenuates radiation-induced lung injuries in mice. Exp Lung Res2014; 40(2): 77–85.
233.
WilsonMSMadalaSKRamalingamTR, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med2010; 207(3): 535–552.
234.
WohlfahrtTRauberSUebeS, et al. PU.1 controls fibroblast polarization and tissue fibrosis. Nature2019; 566(7744): 344–349.
235.
ElhaiMAvouacJHoffmann-VoldAM, et al. OX40L blockade protects against inflammation-driven fibrosis. Proc Natl Acad Sci USA2016; 113(27): E3901–E3910.
236.
AbreuMTTaylorKDLinYC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology2002; 123(3): 679–688.
237.
HendersonNCArnoldTDKatamuraY, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med2013; 19(12): 1617–1624.
238.
LevineDRockeyDCMilnerTA, et al. Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. Am J Pathol2000; 156(6): 1927–1935.
239.
WynnTA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Investig2007; 117(3): 524–529.
240.
WaliMAEidRAAl-HomranyMA. Smooth muscle changes in the cephalic vein of renal failure patients before use as an arteriovenous fistula (AVF). J Smooth Muscle Res2002; 38(3): 75–85.
241.
Vazquez-PadronRIAllonM. New insights into dialysis vascular access: impact of preexisting arterial and venous pathology on AVF and AVG outcomes. Clin J Am Soc Nephrol2016; 11(8): 1495–1503.
242.
ZhaoJJourd’heuilFLXueM, et al. Dual function for mature vascular smooth muscle cells during arteriovenous fistula remodeling. J Am Heart Assoc2017; 6(4): e004891.
243.
ZhaoJWuWZhangW, et al. Selective expression of TSPAN2 in vascular smooth muscle is independently regulated by TGF-β1/SMAD and myocardin/serum response factor. FASEB J2017; 31(6): 2576–2591.
244.
MishraPKTyagiNSenU, et al. H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol2010; 298(2): H451–H456.
245.
AllonMLitovskySYoungCJ, et al. Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients. Am J Kidney Dis2013; 62(6): 1122–1129.
246.
DuqueJCTabbaraMMartinezL, et al. Similar degree of intimal hyperplasia in surgically detected stenotic and nonstenotic arteriovenous fistula segments: a preliminary report. Surgery2018; 163(4): 866–869.
247.
HernandezDRApplewhiteBMartinezL, et al. Inhibition of lysyl oxidase with β-aminopropionitrile improves venous adaptation after arteriovenous fistula creation. Kidney3602021; 2(2): 270–278.
248.
CaiCKilariSSinghAK, et al. Differences in transforming growth Factor-β1/BMP7 signaling and venous fibrosis contribute to female Sex differences in arteriovenous fistulas. J Am Heart Assoc2020; 9(16): e017420.
249.
HeineGHUlrichCSesterU, et al. Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int2003; 64(3): 1101–1107.
250.
StrackeSKonnerKKöstlinI, et al. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int2002; 61(3): 1011–1019.
251.
GaoFChambonPTellidesG, et al. Disruption of TGF-β signaling in smooth muscle cell prevents flow-induced vascular remodeling. Biochem Biophys Res Commun2014; 454(1): 245–250.
252.
SerralheiroPSoaresACosta AlmeidaCM, et al. TGF-β1 in vascular wall pathology: unraveling chronic venous insufficiency pathophysiology. Int J Mol Sci2017; 18(12): 2534.
253.
YunSHSimEHGohRY, et al. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int2016; 2016:9060143.
254.
FuruyaMTanakaRMiyagiE, et al. Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis. Cancer Biol. Ther2012; 13(8): 671–680.
255.
MaierMGeigerEVHenrichD, et al. Platelet factor 4 is highly upregulated in dendritic cells after severe trauma. Mol. Med2009; 15(11–12): 384–391.
256.
RavidKBeelerDLRabinMS, et al. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci USA1991; 88(4): 1521–1525.
257.
SchaffnerARhynPSchoedonG, et al. Regulated expression of platelet factor 4 in human monocytes: role of PARs as a quantitatively important monocyte activation pathway. J. Leukoc. Biol2005; 78(1): 202–209.
258.
DeuelTFSeniorRMChangD, et al. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA1981; 78(7): 4584–4587.
259.
ThomasMRStoreyRF. The role of platelets in inflammation. Thromb. Haemost2015; 114(3): 449–458.
260.
BebawySTGorkaJHyersTM, et al. In vitro effects of platelet factor 4 on normal human neutrophil functions. J Leukoc Biol1986; 39(4): 423–434.
261.
LiuCYBattagliaMLeeSH, et al. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25– (nonregulatory) T cells. J Immunol2005; 174(5): 2680–2686.
262.
ScheuererBErnstMDürrbaum-LandmannI, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood2000; 95(4): 1158–1166.
263.
MartíFBertranELluciàM, et al. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol2002; 72(3): 590–597.
264.
StruyfSSalogniLBurdickMD, et al. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood2011; 117(2): 480–488.
265.
LasagniLFrancalanciMAnnunziatoF, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med2003; 197(11): 1537–1549.
266.
MuellerAMeiserAMcDonaghEM, et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol2008; 83(4): 875–882.
267.
FoxJMKausarFDayA, et al. CXCL4/Platelet factor 4 is an agonist of CCR1 and drives human monocyte migration. Sci Rep2018; 8(1): 9466.
268.
SachaisBSKuoANassarT, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood2002; 99(10): 3613–3622.
ZilberbergAYanivAGazitA. The low density lipoprotein receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and down-regulates the canonical Wnt signaling pathway. J Biol Chem2004; 279(17): 17535–17542.
271.
AttisanoLWranaJL. Signal transduction by the TGF-beta superfamily. Science2002; 296(5573): 1646–1647.
272.
GuoXWangXF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res2009; 19(1): 71–88.
273.
AidoudiSBujakowskaKKiefferN, et al. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS One2008; 3(7): e2657.
274.
LishkoVKYakubenkoVPUgarovaTP, et al. Leukocyte integrin Mac-1 (CD11b/CD18, αMβ2, CR3) acts as a functional receptor for platelet factor 4. J Biol Chem2018; 293(18): 6869–6882.
275.
WhitsonRHWongWLItakuraK. Platelet factor 4 selectively inhibits binding of TGF-β1 to the type I TGF-β1 receptor. J Cell Biochem1991; 47(1): 31–42.
276.
NakerakantiSTrojanowskaM. The role of TGF-β receptors in fibrosis. Open Rheumatol J2012; 6:156–162.
277.
BakerABEttensonDSJonasM, et al. Endothelial cells provide feedback control for vascular remodeling through a mechanosensitive autocrine TGF-beta signaling pathway. Circ. Res2008; 103(3): 289–297.
278.
EgorovaADVan der HeidenKVan de PasS, et al. Tgfβ/Alk5 signaling is required for shear stress induced klf2 expression in embryonic endothelial cells. Dev Dyn2011; 240(7): 1670–1680.
279.
González-NúñezMMuñoz-FélixJMLópez-NovoaJM. The ALK-1/Smad1 pathway in cardiovascular physiopathology: a new target for therapy?Biochim Biophys Acta2013; 1832(10): 1492–1510.
280.
GoumansMJValdimarsdottirGItohS, et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J2002; 21(7): 1743–1753.
281.
TangYYangXFrieselRE, et al. Mechanisms of TGF-β-induced differentiation in human vascular smooth muscle cells. J Vasc Res2011; 48(6): 485–494.
282.
WalsheTEdela PazNGD’AmorePA. The role of shear-induced transforming growth factor-β signaling in the endothelium. Arterioscler Thromb Vasc Biol2013; 33(11): 2608–2617.
283.
BhattDLStoneGWMahaffeyKW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. New Engl J Med2013; 368(14): 1303–1313.
284.
MurataSMaruyamaTNowatariT, et al. Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis. Int J Mol Sci2014; 15(4): 5412–5425.
285.
RahmanMGustafssonDWangY, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets2014; 25(4): 257–263.
286.
ZhanTWeiTDongL, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol2020; 120:83–92.
287.
Silva-CardosoSCTaoWAngiolilliC, et al. CXCL4 links inflammation and fibrosis by reprogramming monocyte-derived dendritic cells in vitro. Front Immunol2020; 11:2149.
288.
GleitzHFEDugourdAJFLeimkühlerNB, et al. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood2020; 136(18): 2051–2064.
289.
GabrielliAAvvedimentoEVKriegT. Scleroderma. New Engl J Med2009; 360(19): 1989–2003.
290.
LandeRMennellaAPalazzoR, et al. Anti-CXCL4 antibody reactivity is present in systemic sclerosis (SSc) and correlates with the SSc type I interferon signature. Int J Mol Sci2020; 21(14): 5102.
291.
Ah KioonMDTripodoCFernandezD, et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med2018; 10(423): eaam8458.
292.
LandeRLeeEYPalazzoR, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. Nat Commun2019; 10(1): 1731.
293.
van BonLAffandiAJBroenJ, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. New Engl J Med2014; 370(5): 433–443.
294.
VolkmannERTashkinDPRothMD, et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther2016; 18(1): 305.
295.
ZhangLZhuYZhangD, et al. Platelet factor 4 protects kidney allograft in a rat kidney transplantation model. Inflammation2015; 38(2): 520–526.
296.
TabbaraMDuqueJCMartinezL, et al. Pre-existing and postoperative intimal hyperplasia and arteriovenous fistula outcomes. Am J Kidney Dis2016; 68(3): 455–464.
297.
WangYKrishnamoorthyMBanerjeeR, et al. Venous stenosis in a pig arteriovenous fistula model: anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant2007; 23(2): 525–533.
298.
LiLTerryCMBlumenthalDK, et al. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant2007; 22(11): 3139–3146.
299.
MisraSDohertyMGWoodrumD, et al. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int2005; 68(6): 2890–2900.
300.
ZabiniDNagarajCStacherE, et al. Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One2012; 7(8): e43793.
301.
BorderWAOkudaSLanguinoLR, et al. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int1990; 37(2): 689–695.
302.
HaberstrohUZahnerGDisserM, et al. TGF-beta stimulates rat mesangial cell proliferation in culture: role of PDGF beta-receptor expression. Am J Physiol1993; 264(2 Pt 2): F199–F205.
